Aktien Sensor

AbbVie Inc. has reported strong Q2 earnings, with its stock price more than doubling from its 52-week low and the company raising its 2025 outlook.

Merck KGaA’s stock price has surged to a 52-week high, driven by the company’s focus on the growing Cell Culture Market and positive market trends.

Novo Nordisk’s stock price has plummeted by 30% after the company revised its annual forecast, with institutional investors selling shares and small investors buying in anticipation of a potential rebound.

Argenx SE is under investigation by Pomerantz Law Firm, potentially impacting its stock price and market performance.

Regeneron Pharmaceuticals’ stock price has surged, but a mixed bag of earnings and a regulatory setback for its lymphoma therapy, odronextamab, raise concerns about the company’s ability to execute on its growth plans.

Amgen reaffirms its quarterly dividend at $2.38 per share, demonstrating its commitment to delivering value to investors despite market fluctuations.

Zoetis Inc is set to release its Q2 earnings report, with investors watching closely to see if the company can maintain its strong performance and overcome increased short interest.

Alnylam Pharmaceuticals’ groundbreaking Amvuttra treatment has driven significant growth, surpassing a $50 billion market value and exceeding analyst estimates, with a bright future predicted.

GSK PLC’s stock price has surged following significant developments, including partnerships worth up to $20.75 billion and $120 billion, increasing trading volume and investor interest.

Avantor Inc’s Q2 earnings have been disastrous, with plummeting revenue and a significant decline in stock price, prompting a need for drastic changes to the company’s business model.